title: Local anesthetics worsen renal function after ischemia-reperfusion injury in rats.
abstract: Local anesthetics are widely used during the perioperative period, even in patients with preexisting renal disease. However, local anesthetics have been shown to cause cell death in multiple cell lines, including human kidney proximal tubule cells. We questioned whether local anesthetics potentiate renal dysfunction after ischemia-reperfusion (I/R) injury in vivo. Rats were implanted with subcutaneous miniosmotic pumps that continuously delivered lidocaine (2 mg.kg-1.h-1), bupivacaine (0.4 mg.kg-1.h-1), tetracaine (1 mg.kg-1.h-1), or saline vehicle, and 6 h later the rats were subjected to 30 min of renal ischemia or to sham operation. Renal function was assessed by measurement of plasma creatinine at 24 and 48 h after renal I/R injury in the presence or absence of chronic infusions of local anesthetics and correlated to histological changes indicative of necrosis. The degree of renal apoptosis was assessed by three methods: 1) DNA fragmentation detected by terminal deoxynucleotidyl transferase biotin-dUTP nick-end labeling staining, 2) DNA laddering detected after agarose gel electrophoresis, and 3) morphological identification of apoptotic tubules at the corticomedullary junction. We also measured the expression of the proinflammatory markers ICAM-1 and TNF-alpha. Continuous local anesthetic infusion with renal I/R injury resulted in an increased magnitude and duration of renal dysfunction compared with the saline-infused I/R group. Additionally, both apoptotic and necrotic renal cell death as well as inflammatory changes were significantly potentiated in local anesthetic-treated rat kidneys. Local anesthetic infusion alone without I/R injury had no effect on renal function. We conclude that local anesthetics potentiated renal injury after I/R by increasing necrosis, apoptosis, and inflammation.
mesh_terms: D000779:Anesthetics, Local / Q000097:blood / Q000494:pharmacology*; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002045:Bupivacaine / Q000097:blood / Q000494:pharmacology*; D015870:Gene Expression; D006339:Heart Rate / Q000187:drug effects; D020287:In Situ Nick-End Labeling; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics / Q000378:metabolism; D007375:Interleukin-1 / Q000235:genetics; D007684:Kidney Tubules / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology*; D007962:Leukocytes / Q000473:pathology; D008012:Lidocaine / Q000097:blood / Q000494:pharmacology; D008297:Male; D009336:Necrosis; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000473:pathology / Q000503:physiopathology*; D013748:Tetracaine / Q000097:blood / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics
chemical_list: D000779:Anesthetics, Local; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D013748:Tetracaine; D018799:Intercellular Adhesion Molecule-1; D008012:Lidocaine; D002045:Bupivacaine